{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T20:07:59Z","timestamp":1772309279590,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biotechnol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Never in mitosis gene-A (NIMA)-related expressed kinase 2 (NEK2) is a serine\/threonine protein kinase regulated by the cell cycle. The purpose of this study was to obtain NEK2 protein to prepare an anti-NEK2 monoclonal antibody (mAb) and explore the application of the anti-NEK2 mAb of therapeutic and diagnostic in hepatocellular carcinoma (HCC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The <jats:italic>NEK2<\/jats:italic> gene sequence was cloned from the normal liver cell line HL7702, and the full-length <jats:italic>NEK2<\/jats:italic> gene sequence was cloned into the prokaryotic expression vector pET30a and transformed into <jats:italic>Escherichia coli<\/jats:italic> BL21 (DE3) cells. The recombinant fusion protein was obtained under optimized conditions and injected in BALB\/c mice to prepare an anti-NEK2 mAb. By screening, we obtained a stable hybridoma cell line named 3A3 that could stably secrete anti-NEK2 mAb. Anti-NEK2 3A3 mAb was purified from ascites fluid. The isotype was IgG1, and the affinity constant (K<jats:sub>aff<\/jats:sub>) was 6.0\u2009\u00d7\u200910<jats:sup>8<\/jats:sup> L\/mol. Western blot, indirect enzyme-linked immunosorbent assay (iELISA), immunofluorescence and immunocytochemical analyses showed that the mAb could specifically recognize the NEK2 protein. MTT assays showed that the mAb 3A3 could inhibit the proliferation of HCC cells. KEGG pathway analysis showed that NEK2 might affected pathways of the cell cycle. Moreover, NEK2-related genes were mainly enriched in the S and G2 phases and might act as tumor-promoting genes by regulating the S\/G2 phase transition of HCC cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>An anti-NEK2 mAb with high potency, high affinity and high specificity was prepared by prokaryotic expression system in this study and may be used in the establishment of ELISA detection kits and targeted treatment of liver cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12896-021-00717-3","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T05:02:32Z","timestamp":1635310952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Preparation of an anti-NEK2 monoclonal antibody and its application in liver cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Qiuli","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lichao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"issue":"6966","key":"717_CR1","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nature02166","volume":"426","author":"J Andersen","year":"2003","unstructured":"Andersen J, Wilkinson C, Mayor T, Mortensen P. Proteomic characterization of the human centrosome by protein correlation profiling. Nature. 2003;426(6966):570\u20134.","journal-title":"Nature"},{"issue":"2","key":"717_CR2","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/emboj\/17.2.470","volume":"17","author":"AM Fry","year":"1998","unstructured":"Fry AM, Meraldi P, Nigg EA. A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators. EMBO J. 1998;17(2):470.","journal-title":"EMBO J"},{"issue":"7015","key":"717_CR3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature03099","volume":"432","author":"H Rajagopalan","year":"2004","unstructured":"Rajagopalan H, Lengauer C. Aneuploidy and cancer. Nature. 2004;432(7015):338\u201341.","journal-title":"Nature"},{"issue":"3","key":"717_CR4","first-page":"441","volume":"20","author":"DH Wai","year":"2002","unstructured":"Wai DH, Schaefer K, Schramm A, Korsching E, Van Valen F, Ozaki T, Boecker W, Schweigerer L, Dockhorn-Dworniczak B, Poremba C. Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays. Int J Oncol. 2002;20(3):441\u201351.","journal-title":"Int J Oncol"},{"issue":"3","key":"717_CR5","first-page":"1023","volume":"39","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Wang W, Wang Y, Huang X, Zhang Z, Chen B, Xie W, Li S, Shen S, Peng B. NEK2 promotes hepatocellular carcinoma migration and invasion through modulation of the epithelial-mesenchymal transition. Oncol Rep. 2018;39(3):1023\u201333.","journal-title":"Oncol Rep"},{"issue":"11","key":"717_CR6","first-page":"2364","volume":"9","author":"Y Li","year":"2019","unstructured":"Li Y, Chen L, Feng L, Zhu M, Shen Q, Fang Y, Liu X, Zhang X. NEK2 promotes proliferation, migration and tumor growth of gastric cancer cells via regulating KDM5B\/H3K4me3. Am J Cancer Res. 2019;9(11):2364\u201378.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"717_CR7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1089\/cmb.2019.0208","volume":"27","author":"S Liu","year":"2020","unstructured":"Liu S, Tian W, Li B. Integrative bioinformatics analysis identifies NEK2 as a potential biomarker in head and neck squamous cell carcinoma. J Comput Biol. 2020;27(1):100\u20138.","journal-title":"J Comput Biol"},{"key":"717_CR8","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3389\/fonc.2019.00613","volume":"9","author":"S Pan","year":"2019","unstructured":"Pan S, Zhan Y, Chen X, Wu B, Liu B. Identification of biomarkers for controlling cancer stem cell characteristics in bladder cancer by network analysis of transcriptome data stemness indices. Front Oncol. 2019;9:613.","journal-title":"Front Oncol"},{"issue":"2","key":"717_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3892\/ijo.2017.3837","volume":"50","author":"G Li","year":"2017","unstructured":"Li G, Zhong Y, Shen Q, Zhou Y, Deng X, Li C, Chen J, Zhou Y, He M. NEK2 serves as a prognostic biomarker for hepatocellular carcinoma. Int J Oncol. 2017;50(2):405\u201313.","journal-title":"Int J Oncol"},{"issue":"9","key":"717_CR10","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/cas.12993","volume":"107","author":"T Kokuryo","year":"2016","unstructured":"Kokuryo T, Hibino S, Suzuki K, Watanabe K, Yokoyama Y, Nagino M, Senga T, Hamaguchi M. Nek2 siRNA therapy using a portal venous port-catheter system for liver metastasis in pancreatic cancer. Cancer Sci. 2016;107(9):1315\u201320.","journal-title":"Cancer Sci"},{"issue":"20","key":"717_CR11","doi-asserted-by":"publisher","first-page":"9637","DOI":"10.1158\/0008-5472.CAN-07-1489","volume":"67","author":"T Kokuryo","year":"2007","unstructured":"Kokuryo T, Senga T, Yokoyama Y, Nagino M, Nimura Y, Hamaguchi M. Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangiocarcinoma. Can Res. 2007;67(20):9637\u201342.","journal-title":"Can Res"},{"issue":"5","key":"717_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.coph.2012.08.001","volume":"12","author":"NA Buss","year":"2012","unstructured":"Buss NA, Henderson SJ, Mcfarlane M, Shenton JM, de Haan L. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol. 2012;12(5):615\u201322.","journal-title":"Curr Opin Pharmacol"},{"issue":"4","key":"717_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41571-019-0299-9","volume":"17","author":"K Goutsouliak","year":"2020","unstructured":"Goutsouliak K, Veeraraghavan J, Sethunath V, Angelis CD, Schiff R. Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol. 2020;17(4):233\u201350.","journal-title":"Nat Rev Clin Oncol"},{"key":"717_CR14","volume-title":"Practice and theory of enzyme immunoassays","author":"P Tijssen","year":"1985","unstructured":"Tijssen P. Practice and theory of enzyme immunoassays. Amsterdam: Elsevier Science Ltd; 1985."},{"issue":"3","key":"717_CR15","first-page":"1851","volume":"41","author":"C Chen","year":"2019","unstructured":"Chen C, Li X, Gu M, Di R, Kang N, Wang L, Lai Y, Liu Y, Ji X. Biological characterisation and application of human MTH1 and monoclonal antibody preparation. Oncol Rep. 2019;41(3):1851\u201362.","journal-title":"Oncol Rep"},{"key":"717_CR16","first-page":"46","volume":"258","author":"P Unberath","year":"2019","unstructured":"Unberath P, Knell C, Prokosch HU, Christoph J. Developing new analysis functions for a translational research platform: extending the cBioPortal for cancer genomics. Stud Health Technol Inform. 2019;258:46\u201350.","journal-title":"Stud Health Technol Inform"},{"key":"717_CR17","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28:1947\u201351.","journal-title":"Protein Sci"},{"key":"717_CR18","doi-asserted-by":"publisher","first-page":"105628","DOI":"10.1016\/j.pep.2020.105628","volume":"172","author":"J D\u00e9n","year":"2020","unstructured":"D\u00e9n J, Mushtaq AU, Dingeldein A, Wallgren M, Grbner G. A novel recombinant expression and purification approach for the full-length anti-apoptotic membrane protein Bcl-2. Protein Expr Purif. 2020;172:105628.","journal-title":"Protein Expr Purif"},{"issue":"2","key":"717_CR19","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s12033-012-9610-z","volume":"54","author":"ND Lamb-Palmer","year":"2013","unstructured":"Lamb-Palmer ND, Singh M, Dalton JP, Singh J. Prokaryotic expression and purification of soluble maize Ac transposase. Mol Biotechnol. 2013;54(2):685\u201391.","journal-title":"Mol Biotechnol"},{"key":"717_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.toxicon.2014.10.017","volume":"92","author":"TTT Vu","year":"2014","unstructured":"Vu TTT, Jeong B, Yu J, Koo B, Jo S, Robinson RC, Choe H. Soluble prokaryotic expression and purification of crotamine using an N-terminal maltose-binding protein tag. Toxicon. 2014;92:157\u201365.","journal-title":"Toxicon"},{"issue":"1","key":"717_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12896-019-0543-5","volume":"19","author":"Y Gao","year":"2019","unstructured":"Gao Y, Sang FF, Meng DL, Wang Y, Chen DK. Preparation of a novel monoclonal antibody against caprine interleukin-17A and its applications in immunofluorescence and immunohistochemistry assays. BMC Biotechnol. 2019;19(1):47.","journal-title":"BMC Biotechnol"},{"issue":"6","key":"717_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/mab.2017.0033","volume":"36","author":"Y Xi","year":"2017","unstructured":"Xi Y, Zhang Y, Fang J, Whittaker K, Luo S, Huang RP. Prokaryotic expression of hepatitis C virus-NS3 protein and preparation of a monoclonal antibody. Monoclonal Antibodies Immunodiagnosis Immunother. 2017;36(6):251\u20138.","journal-title":"Monoclonal Antibodies Immunodiagnosis Immunother"},{"key":"717_CR23","volume-title":"Monoclonal antibodies principles and practice","author":"JW Goding","year":"1986","unstructured":"Goding JW. Monoclonal antibodies principles and practice. 3rd ed. Boston: Academic Press; 1986.","edition":"3"},{"key":"717_CR24","doi-asserted-by":"publisher","first-page":"120510","DOI":"10.1016\/j.jhazmat.2019.03.129","volume":"378","author":"R Wang","year":"2019","unstructured":"Wang R, Zhong Y, Wang J, Yang H, Wang S. Development of an ic-ELISA and immunochromatographic strip based on IgG antibody for detection of \u03c9-conotoxin MVIIA. J Hazard Mater. 2019;378:120510.","journal-title":"J Hazard Mater"},{"issue":"23","key":"717_CR25","doi-asserted-by":"publisher","first-page":"E5894","DOI":"10.3390\/ijms20235894","volume":"20","author":"HW Lee","year":"2019","unstructured":"Lee HW, Son E, Lee K, Lee Y. Promising therapeutic efficacy of GC1118, an anti-EGFR antibody, against KRAS mutation-driven colorectal cancer patient-derived xenografts. Int J Mol Sci. 2019;20(23):E5894.","journal-title":"Int J Mol Sci"},{"key":"717_CR26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2147\/CMAR.S147326","volume":"9","author":"RM Gorczynski","year":"2017","unstructured":"Gorczynski RM, Zhu F. Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200. Cancer Manag Res. 2017;9:601\u20139.","journal-title":"Cancer Manag Res"},{"key":"717_CR27","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3389\/fimmu.2017.01001","volume":"8","author":"I Trenevska","year":"2017","unstructured":"Trenevska I, Li D, Banham AH. Therapeutic antibodies against intracellular tumor antigens. Front Immunol. 2017;8:1001.","journal-title":"Front Immunol"},{"issue":"1","key":"717_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-019-02189-8","volume":"18","author":"CH Jiang","year":"2020","unstructured":"Jiang CH, Yuan X, Li JF, Xie YF, Hu JM. Bioinformatics-based screening of key genes for transformation of liver cirrhosis to hepatocellular carcinoma. J Transl Med. 2020;18(1):1\u201311.","journal-title":"J Transl Med"},{"issue":"19","key":"717_CR29","first-page":"4423","volume":"125","author":"AM Fry","year":"2012","unstructured":"Fry AM, O\u2019Regan L, Sabir SR, Bayliss R. Cell cycle regulation by the NEK family of protein kinases. J Cell Sci. 2012;125(19):4423\u201333.","journal-title":"J Cell Sci"}],"container-title":["BMC Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-021-00717-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12896-021-00717-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-021-00717-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T05:03:26Z","timestamp":1635311006000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbiotechnol.biomedcentral.com\/articles\/10.1186\/s12896-021-00717-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["717"],"URL":"https:\/\/doi.org\/10.1186\/s12896-021-00717-3","relation":{},"ISSN":["1472-6750"],"issn-type":[{"value":"1472-6750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"15 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments obeyed the protocols approved by the Animal Ethics Committee of the Guangxi Medical University. And the study was carried out in accordance with ARRIVE guidelines. In addition, all methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}